Article Text

other Versions

PDF
Increasing the infliximab dose in rheumatoid arthritis patients: a randomized, double blind study failed to confirm its efficacy
  1. K Pavelka (pavelka{at}revma.cz)
  1. Institute of Rheumatology, Prague, Czech Republic
    1. K Jarošová (jaro{at}revma.cz)
    1. Institute of Rheumatology, Prague, Czech Republic
      1. D Suchý (suchyd{at}fnplzen.cz)
      1. Department of Clinical Pharmacology, Pilsen, Czech Republic
        1. L Šenolt (seno{at}revma.cz)
        1. Institute of Rheumatology, Prague, Czech Republic
          1. K Chroust (chroust{at}iba.muni.cz)
          1. Centre for Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
            1. L Dušek (dusek{at}iba.muni.cz)
            1. Centre for Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
              1. J Vencovský (venc{at}revma.cz)
              1. Institute of Rheumatology, Prague, Czech Republic

                Abstract

                Objective: To evaluate the effect of infliximab dose escalation in incomplete responders in a randomized controlled trial.

                Methods: We enrolled 141 RA patients treated with infliximab for 12 months (3 mg/kg; intervals: 0, 2, 6, and then 8 weeks) who responded to the drug [disease activity score (DAS28) decrease >1.2)] but who were not in remission (DAS28>2.6). Patients were randomized into arm A, 3 mg/kg, and arm B, 5 mg/kg infliximab every 8 weeks. Outcome measures included DAS28, its components, and C-reactive protein (CRP).

                Results: There were no significant differences in changes in DAS28, its components, or CRP in patients in arms A and B during the 12 months of treatment. All patients showed a DAS28 decrease >0.6 after 28 weeks. Eleven patients interrupted therapy in arm A and 14 in arm B. Infusion reactions and non-serious adverse events were observed in 4.2% and 28.2% of arm A patients and in 7.2% and 47.8% of arm B patients. The frequency of serious adverse events was comparable between arms A and B (16.9% and 15.9%, respectively), and the frequency of serious infections was not significantly higher in the higher dose group (5.8%) than in the lower dose group (5.6%).

                Conclusions: In this setting, increasing the infliximab dose from 3 to 5 mg/kg in RA patients with residual disease activity did not improve efficacy but moderately increased toxicity. These data indicate that a switch to another biological treatment would be a more appropriate strategy in incomplete responders.

                Statistics from Altmetric.com

                Request permissions

                If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

                Linked Articles